Type II diabetes mellitus is associated with decreased measures of lung function in a clinical setting  by Klein, Oana L. et al.
Respiratory Medicine (2011) 105, 1095e1098ava i lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / rmedSHORT COMMUNICATION
Type II diabetes mellitus is associated with
decreased measures of lung function in a clinical
settingOana L. Klein a,*, David Meltzer b,d, Mercedes Carnethon c,
Jerry A. Krishnan b,daDepartment of Medicine, Northwestern University Feinberg School of Medicine, United States
bDepartment of Medicine, University of Chicago Pritzker School of Medicine, United States
cDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, United States
dDepartment of Health Studies, University of Chicago Pritzker School of Medicine, United States
Received 8 February 2011; accepted 8 March 2011
Available online 29 March 2011KEYWORDS
Diabetes;
Lung function;
Forced expiratory
volume in first second
(FEV1);
Forced vital capacity
(FVC);
Heart failure* Corresponding author. Division of H
E. Ontario Street, 7th floor, Chicago,
E-mail address: oklein@nmh.org (O
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2011.03.010Summary
Aims: Type II diabetes mellitus has been associated with reduced forced expiratory volume in
first second (FEV1) and forced vital capacity (FVC). We investigated if this relationship is main-
tained in a clinical setting, independent of respiratory infections and heart failure.
Methods: Pulmonary function tests and discharge summaries of 639 adults 18e80 years of age,
of different races/ethnicities, seen at an urban hospital during a two years period were re-
viewed. After selection of patients based on inclusion/exclusion criteria, 286 patients were
included in our analysis. Using multivariable linear regression we examined cross-sectional
differences of FEV1 and FVC between patients with and without diabetes, adjusting for age,
sex, race/ethnicity, BMI, smoking and respiratory symptoms.
Results: Patients with diabetes were older (63  1 vs. 56  1), more likely to be African-Amer-
icans (30% vs. 25%) and Hispanics (40% vs. 31%), have respiratory symptoms (79% vs. 68%), and
a higher BMI (34.2  1.0 vs. 30.1  0.6), compared to patients without diabetes. The distribu-
tion of women and smoking among the two groups were similar. The mean unadjusted percent
predicted values of FEV1 and FVC in patients with diabetes were lower than in those without
diabetes, and remained significantly reduced after adjustment (77.3  0.5 vs. 82.0  0.3,
p < 0.01 for FEV1 and 73.8  0.6 vs. 82.8  0.3, p < 0.01 for FVC, respectively).ospital Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, 211
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compared to their non-diabetic counterparts, independent of respiratory infections and heart
failure.
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A quarter of the adults over age 60 have type 2 diabetes,
and the Centers for Disease Control and Prevention forecast
a near-doubling of its incidence over the next 40 years.1
Microvascular diabetic complications are due to chronic
hyperglycemia and formation of pro-inflammatory glycosy-
lated proteins, which subsequently deposit within the small
vessels, leading to microangiopathy.2 The pulmonary alve-
olar-capillary network constitutes the largest microvascular
organ in the body, and therefore the lungs can potentially
be affected by diabetic microangiopathy.3,4 In fact, prior
epidemiological5,6 and clinical studies7 have found reduced
lung function in adults with diabetes, independent of other
risk factors such as smoking and obesity. We8 and others9
summarized the results of these studies in two recently
published qualitative and quantitative reviews.
Patients with diabetes have an increased risk of devel-
oping respiratory infections10 or heart failure,11 and these
can contribute to decreased lung function. However, none
of the previous studies accounted for these potential
cofounders.
In the present study, we investigated the relationship
between lung function and diabetes in a broad spectrum of
patients seen at an urban hospital, accounting for potential
respiratory infections and heart failure.
Methods
Subjects
We conducted a retrospective review of all pulmonary
function tests (PFTs) performed at Advocate Illinois Masonic
Medical Center, a 551-bed urban teaching hospital,
between January 2004 and September 2006. Medical
records from 639 adults, ages 18e80 years old, men and
women, of three different races/ethnicities (Caucasians,
African-Americans, and Hispanics) were queried. During
that time period, PFT records included the reason for
referral (presence of symptoms, pre-employment screen-
ing, preoperative evaluation etc), in addition to the test
results. When we encountered repeated PFTs for the same
patient, we included only the most recent test. Using ICD9
codes, we excluded patients with a history of type I dia-
betes as well as diseases known to cause abnormal lung
function (Fig. 1). Further, based on PFT’s questionnaires
containing patients self reported smoking history and race/
ethnicity, we excluded patients with incomplete smoking
history or race data. Finally, we excluded patients who
were hospitalized within the prior three months due to
pneumonia or acute exacerbation of heart failure. The final
sample included 286 patients: 210 without diabetes and
76 patients with type II diabetes.Data collection
PFT and medical records were abstracted and the following
information recorded: forced expiratory volume in first
second (FEV1), forced vital capacity (FVC); demographics
(age, sex, race/ethnicity, height and weight); smoking
history; history of diseases known to cause abnormal lung
function (Fig. 1); history of type I and II diabetes; history of
heart failure; presence of respiratory symptoms at the time
of PFT’s; hospitalization within the prior three months due
to pneumonia or acute exacerbation of heart failure. Body
mass index (BMI) was calculated as weight (kg) divided by
height squared (m2).
Pulmonary function tests
Patients were referred for PFTs for pulmonary symptoms,
preoperative evaluation or pre-employment screening.
Standard spirometry was performed by trained and certified
pulmonary technicians in accordance with the American
Thoracic Society Guidelines.12
Statistical analysis
Data are reported as means and standard errors or
proportion of participant characteristics. Baseline charac-
teristics of patients with and without diabetes were
compared using t-tests or chi-square tests.
Differences in FEV1 and FVC between patients with and
without diabetes were first examined using unadjusted raw
values (by t-tests), then using multivariable linear regres-
sion, adjusting for age, sex, race/ethnicity, smoking, BMI
and presence of respiratory symptoms. Statistical signifi-
cance was determined at p < 0.05.
All analyses were carried using STATA version 11 (College
Station, TX) statistical analysis software.
Results
Patients with diabetes were significantly older, more likely
to be African-Americans and Hispanics, overweight and had
a higher prevalence of respiratory symptoms (shortness
of breath and/or cough) compared to their non-diabetic
counterparts (Table 1). There were no differences in the
distribution of women and smokers between the diabetic
and non-diabetic patients. The mean unadjusted percent
predicted values for FEV1 and FVC were significantly lower
in patients with diabetes compared to patients without
(Table 1). After adjustment for age, sex, race/ethnicity,
smoking and presence of respiratory symptoms, the mean
percent predicted values were 76.5  0.4 vs. 82.2  0.3,
p< 0.01 for FEV1, and 72.9  0.6 vs. 83.1  0.5, p< 0.01 for
FVC, in patients with and without diabetes, respectively.
Figure 1 Inclusion and exclusion criteria.
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and FVC between patients with and without diabetes were
attenuated; however, the mean percent predicted values of
FEV1 and FVC remained significantly reduced in patients
with diabetes compared to those without (77.3  0.5 vs.
82.0  0.3, p < 0.01 for FEV1 and 73.8  0.6 vs. 82.8  0.3,
p < 0.01 for FVC, respectively).Discussion
Our analysis of PFTs was performed in a clinical setting and
revealed a significant reduction in the lung function in
patients with diabetes compared to those without, inde-
pendent of other risk factors such as smoking and obesity,
as well as the presence of respiratory symptoms. Prior
studies examining the association between lung function
and diabetes found that adults with diabetes had reduced
lung function independent of smoking and obesity. In ourTable 1 Baseline characteristics of diabetic and non-diabetic p
Characteristic Diabetic
Age (mean  SE), years 63  1
Women (%) 57
Ethnicity
Caucasian (%) 30
African-American (%) 30
Hispanic (%) 40
BMI (mean  SE), kg/m2 34.2 
Smoking (%) 29
Respiratory symptoms (%) 79
FEV1, % predicted, (mean  SE) 75.3 
FVC, % predicted, (mean  SE) 71.2 
BMI Z body mass index; SE Z standard error.study, the distribution of smoking was similar between the
two groups, but patients with diabetes were more over-
weight and more likely to have respiratory symptoms
compared to those without diabetes. As we used percent
predicted to report lung function volumes (already ad-
justed for age, sex and height), and the two comparison
groups had a similar distribution of smoking, the attenua-
tion in the differences in FEV1 and FVC between patients
with and without diabetes was due to the differences in BMI
and respiratory symptoms between the groups. However,
even after adjustment, FEV1 and FVC remained significantly
reduced in patients with diabetes compared to those
without diabetes.
The novelty of our study is that although prior studies
showed that type II diabetes is associated with reduced lung
function, none of these examined if this association can be
explained by the higher prevalence of respiratory infections
or heart failure in patients with diabetes. In our study, we
excluded patients who were hospitalized for pneumonia oratients referred for pulmonary function tests.
s (n Z 76) Non-diabetics (n Z 210)
56  1
57
44
25
31
1.0 30.1  0.6
28
68
0.7 82.6  0.4
0.7 83.8  0.5
1098 O.L. Klein et al.heart failure exacerbation within three months prior to the
PFTs; we also adjusted for the presence of respiratory
symptoms to account for potential occult respiratory infec-
tions or heart failure at the time of PFTs. Themain limitation
of our study was the lack of chest x-ray and echocardio-
grams, which could have objectively determined the pres-
ence of pneumonia or heart failure at the time of PFTs.
Our findings confirm prior research and showed that the
association between diabetes and reduced lung function is
not explained by the higher prevalence of respiratory
infections or heart failure in patients with diabetes. Future
studies need to establish the biological mechanism to ex-
plain this association.Conflict of interest statement
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